Healthy Clinical Trial
Official title:
Daily Intake of Cocoa Flavanols and Arterial Stiffness in Humans
NCT number | NCT03587883 |
Other study ID # | 547762 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 23, 2018 |
Est. completion date | August 6, 2021 |
Verified date | May 2022 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomized, double-masked and cross-over dietary intervention study to investigate the effects of diet supplementation with cocoa flavanols on arterial stiffness in healthy adult human subjects.
Status | Completed |
Enrollment | 10 |
Est. completion date | August 6, 2021 |
Est. primary completion date | August 6, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 65 Years |
Eligibility | Inclusion Criteria: - 25-65 years old - BMI 18.5 - 34.9 kg/m2 - Weight = 110 pounds - Previously consumed cocoa and peanut products, with no adverse reactions - Having completed physical exercise similar to 5 MET within the last 2 months without having any physical limitations [e.g. i) Brisk walking (at 4 mph); ii) Mowing lawn; iii) Bicycling-light effort (10 mph) and iv) Playing tennis-doubles.] Exclusion Criteria: - Adults unable to consent - Individuals who are not yet adults (infants, children, teenagers) - Pregnant women - Prisoners - Non-English speaking* - BMI = 35 kg/m2 - More than 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity aerobic activity weekly and more than two days a week of muscle strengthening activities that work all major muscle groups (CDC recommended physical activity guidelines for adults) - Allergies to nuts, cocoa and chocolate products - Active avoidance of coffee and caffeinated soft drinks - A history of cardiovascular disease, stroke, renal, hepatic, or thyroid disease - History of clinically significant depression, anxiety or other psychiatric condition - History of difficult blood draws - History of Raynaud's disease - Indications of substance or alcohol abuse within the last 3 years - Current use of herbal, plant or botanical supplements (multi-vitamin/mineral supplements are allowed) - Blood Pressure >140/90 mm Hg - Blood Pressure < 100/60 mm Hg, or heart rate < 50 bpm (due to limitations in the assessment of arterial stiffness - GI tract disorders, previous GI surgery (except appendectomy) - Self-reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food, potentially leading to bloating, cramping or gas) - Diarrhea within the last month, or antibiotic intake within the last month - Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or individuals following diets with significant deviations from the average diet - Metabolic panel results or complete blood counts that are outside of the normal reference range and are considered clinically relevant by the study physician - Cold, flu, or upper respiratory condition at screening - Currently participating in a clinical or dietary intervention study - *Non-English speaking volunteers will be excluded for safety reasons, as we do not have staff that can adequately provide interpretation services that can explain and answer questions with regard to study procedures. |
Country | Name | City | State |
---|---|---|---|
United States | Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis | Davis | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | Mars, Inc. |
United States,
Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. Mol Aspects Med. 2010 Dec;31(6):546-57. doi: 10.1016/j.mam.2010.09.008. Epub 2010 Sep 18. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Individual changes in systolic blood pressure (in office) | assessed as systolic blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Primary | Individual changes in diastolic blood pressure (in office) | assessed as diastolic blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Primary | Individual changes in augmentation index (in office) | assessed as augmentation index | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Primary | Individual changes in central blood pressure (in office) | assessed as central blood pressure | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Primary | Individual changes in blood pressure (at home) | self monitoring blood pressure | Daily for 2 weeks between 0, 2, 4, 6, 8 and 10 weeks of intervention | |
Primary | Individual changes in pulse wave velocity (in office) | assessed as pulse wave velocity | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Primary | Individual changes in lipid profile | Total cholesterol, LDL, HDL and Triglycerides | Baseline and 2, 4, 6, 8 and 10 weeks following intervention | |
Secondary | Individual changes in flavanol metabolites in plasma and urine | flavanol/methylxanthine metabolites in plasma and urine | Baseline and 2, 4, 6, 8, 10 weeks following intervention | |
Secondary | Individual changes in methylxanthine metabolites in plasma and urine | flavanol/methylxanthine metabolites in plasma and urine | Baseline and 2, 4, 6, 8, 10 weeks following intervention | |
Secondary | Individual changes in CMP | comprehensive metabolic panel | Baseline and 2, 4, 6, 8, 10 weeks following intervention | |
Secondary | Individual changes in Step test performance | Volunteers will be asked to step up and down on a platform (7 inches high) at a rate of 23 steps per minute for no more than 3 minutes. Blood pressure will be measured before and after the step test. | Baseline and 2, 4, 6, 8, 10 weeks following intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |